Platelet Counts and Genetic Polymorphisms of Alcohol Dehydrogenase‐1B and Aldehyde Dehydrogenase‐2 in Japanese Alcoholic Men. (19th December 2016)

• Record Type: Journal Article
• Authors: Yokoyama, Akira; Yokoyama, Tetsuji; Mizukami, Takeshi; Matsui, Toshifumi; Kimura, Mitsuru; Matsushita, Sachio; Higuchi, Susumu; Maruyama, Katsuya
• Is Part Of: Alcoholism. Volume 41:Number 1(2017)
• Page Start: 171
• Page End: 178
• Publication Date: 2016-12-19
• Subjects: Alcohol Dehydrogenase‐1B -- Aldehyde Dehydrogenase‐2 -- Platelet -- Liver Disease -- Thrombocytopenia; Alcoholism -- Periodicals; Alcoholism -- Periodicals; Alcoolisme; Electronic journals; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.861005
• DOI: 10.1111/acer.13283
• Languages: English
• ISSNs: 0145-6008

Abstract

Abstract : Background: Thrombocytopenia during intoxication, rebound thrombocytosis during 1 to 3 weeks of abstinence, and subsequent normalization of the platelet count are common in alcoholics. Methods: We evaluated 989 Japanese alcoholic men to identify the effects of genetic polymorphisms of alcohol dehydrogenase‐1B (ADH1B; rs1229984) and aldehyde dehydrogenase‐2 (ALDH2; rs671) on platelet counts during an 8‐week in‐hospital abstinence period. Results: Thrombocytopenia (<15 × 10 4 / μ l) was observed in 25.9% of the subjects upon admission. The platelet counts increased from 21.4 ± 0.3 × 10 4 / μ l (mean ± SE) to 27.6 ± 0.3 × 10 4 / μ l, and a rebound platelet increase of ≥10 × 10 4 / μ l was observed in 28.6% of the patients during the first 2 weeks after admission. By 4 weeks, the mean platelet counts had returned to intermediate levels and remained stable thereafter. The reversible suppression and rebound increase in the platelet counts were more prominent in the slow‐metabolizing ADH1B*1/*1 group than in the fast‐metabolizing ADH1B*2 group. Throughout the 8 weeks, the mean platelet counts of the active ALDH2*1/*1 group were consistently lower than those in the inactive ALDH2*1/*2 group. Cirrhosis was a strong determinant of a lower platelet count. After adjustments for nongenetic factors including cirrhosis, multiple linear regression analyses showed that the ADH1B*1/*1 genotype was associated with a lower platelet count (partial regression coefficient = −1.3 × 10 4 / μ l) on the admission day, but subsequently had a positive effect on the platelet count at 1 and 2 weeks after admission (+1.5 and +3.8 × 10 4 / μ l, respectively). The ALDH2*1/*1 genotype was associated with a lower platelet count (−2.1 to −3.9 × 10 4 / μ l) consistently throughout the 8 weeks. Multiple logistic regression analyses showed that the ADH1B*1/*1 genotype increased the risk of thrombocytopenia upon admission (odds ratio [95% confidence interval] = 1.61 [1.14 to 2.27]) and of a rebound platelet increase during the first 2 weeks (3.86 [2.79 to 5.34]). The ALDH2*1/*1 genotype increased the risk of thrombocytopenia upon admission (1.73 [1.06 to 2.82]). Conclusions: In alcoholics, the ADH1B*1/*1 genotype increased the risk of thrombocytopenia upon admission and of a rebound platelet increase 2 weeks thereafter, while the ALDH2*1/*1 genotype was associated with lower platelet counts throughout the 8‐week hospital stay. Abstract : Thrombocytopenia upon admission and a rebound platelet increase after a 2‐week abstinence period were common among the alcoholics. After adjustments for nongenetic factors including the presence of cirrhosis, the presence of a slow‐metabolizing alcohol dehydrogenase‐1B ( ADH1B*1/*1 genotype) increased the risk of both thrombocytopenia upon admission and the rebound platelet increase after abstinence, whereas the presence of an active aldehyde dehydrogenase‐2 ( ALDH2*1/*1 genotype) was associated with lower platelet counts throughout the 8‐week in‐hospital abstinence period.